Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE,Dextrans,Glycerine
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : OcuMension Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
OcuMension Acquires Alcon Eye Drops with 16.7% Equity, Strategic Partnership Begins
Details : OcuMension will acquire outright, Tears Natural Forte, Bion Tears, Alcaine, Fluorescite, and Cyclogyl, in the Chinese market and AR-15512, a novel topical drug candidate for dry eye.
Product Name : Tears Naturale Forte
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 08, 2024
Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE,Dextrans,Glycerine
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : OcuMension Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
A Safety and Tolerability Study of ILB® in Patients With Amyotrophic Lateral Sclerosis (ALS)
Details : Undisclosed
Product Name : ILB
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
October 15, 2018
Details : Undisclosed
Product Name : ILB
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
August 03, 2018
Lead Product(s) : Dextrans,Inapplicable
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase III
Sponsor : Defence Research and Development Canada
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 17, 2012
Lead Product(s) : Dextrans,Inapplicable
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase III
Sponsor : Defence Research and Development Canada
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
